Journals / Balkan Medical Journal / 2015 / Cilt: 32 - Sayı: 1

Imp3 expression in benign and malignant thyroid tumors and hyperplastic nodules

Pages
30–37
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Methods: Overall, 92 thyroid lesions, including 22 nodular hyperplasia (NH), 14 follicular adenoma (FA), 9 follicular carcinoma (FC), 37 papillary carcinoma (PC) (15 follicular variant), 3 well differentiated carcinoma-not otherwise specified (WDC-NOS), 4 poorly differentiated carcinoma (PDC) and anaplastic carcinoma (AC) were included.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: IMP3, a member of insulin-like growth factor II m RNA binding protein family, seems to be promising in the diagnosis of carcinomas of many organs as well as malignant melanomas and some sarcomas.
📊
Key Findings & Data:The results of the few prior studies indicate that IMP3 has the potential to be useful in distinguishing benign and malignant tumors of thyroid.
💡
Conclusion & Impact:Methods: Overall, 92 thyroid lesions, including 22 nodular hyperplasia (NH), 14 follicular adenoma (FA), 9 follicular carcinoma (FC), 37 papillary carcinoma (PC) (15 follicular variant), 3 well differentiated carcinoma-not otherwise specified (WDC-NOS), 4 poorly differentiated carcinoma (PDC) and anaplastic carcinoma (AC) were included.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: IMP3, a member of insulin-like growth factor II m RNA binding protein family, seems to be promising in the diagnosis of carcinomas of many organs as well as malignant melanomas and some sarcomas. It is postulated that it might be a marker of malig- nancy. The results of the few prior studies indicate that IMP3 has the potential to be useful in distinguishing benign and malignant tumors of thyroid. Aims: We aimed to evaluate the immunohistochemical expression of IMP3 in noneoplastic nodules and benign and malignant tumors of the thyroid. Study Design: Diagnostic accuracy study. Methods: Overall, 92 thyroid lesions, including 22 nodular hyperplasia (NH), 14 follicular adenoma (FA), 9 follicular carcinoma (FC), 37 papillary carcinoma (PC) (15 follicular variant), 3 well differentiated carcinoma-not otherwise specified (WDC-NOS), 4 poorly differentiated carcinoma (PDC) and anaplastic carcinoma (AC) were included. Immunohistochemically, cytoplasmic expression of IMP3 was evaluated in terms of extent and intensity of the staining semi-quantitatively and an immunohistochemical score (IHS) was obtained for each case. A score higher than 2 was considered positive staining. Results: In contrast with previous studies, we observed positive staining in benign lesions, especially in benign tumors. For identifying malignant tumors, the sensitivity of IMP3 was 82.1%, specificity was 33.3%, positive predictive value (PPV) was 65.7% and negative predictive value (NPV) was 54.5%. In distinguishing neoplastic and hyperplastic lesions, the sensitivity was 50%, specificity was 15.7%, PPV was 15.7% and NPV was 50%. The IMP3 expression was similar for FA and well differentiated carcinomas (p=0.434), but there was a significant difference between hyperplastic nodules and FA (p=0.011). Conclusion: Our data suggest that IMP3 is effective in discriminating hyperplastic and neoplastic lesions but not useful in differentiating benign tumors from malignant tumors.

🔖

Cite This Article

KULAÇOĞLU, S., ERKILINÇ, G. (2022). Imp3 expression in benign and malignant thyroid tumors and hyperplastic nodules. Balkan Medical Journal, Cilt: 32 - Sayı: 1, 30–37. https://ajindex.com/articles/461419

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpção LV, Metze K, Ward LS. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malig- nancy. Histopathology 2005
  2. [CrossRef] 2. Scognamiglio T, Hyjek E, Kao J, Chen YT. Diagnostic useful- ness of HBME1, galectin-3, CK19, and CITED1 and evalua- tion of their expression in encapsulated lesions with question- able features of papillary thyroid carcinoma. Am J Clin Pathol 2006
  3. [CrossRef] 3. de Matos LL, Del Giglio AB, Matsubayashi CO, de Lima Farah M, Del Giglio A, da Silva Pinhal MA. Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn Pathol 2012
  4. [CrossRef] 4. Ito Y, Yoshida H, Tomoda C, Miya A, Kobayashi K, Matsuzuka F, et al. Galectin-3 expression in follicular tumours: an immu- nohistochemical study of its use as a marker of follicular carci- noma. Pathology 2005
  5. [CrossRef] 5. Mehrotra P, Okpokam A, Bouhaidar R, Johnson SJ, Wilson JA, Davies BR, et al. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 2004
  6. [CrossRef] 6. Sahoo S, Hoda SA, Rosai J, DeLellis RA. Cytokeratin 19 im- munoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Am J Clin Pathol 2001
  7. [CrossRef] 7. Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R, Khan A, et al. Insulin-like growth factor mRNA Binding protein 3 (IMP3) is dif- ferentially expressed in benign and malignant follicular patterned thyroid tumors. Endocr Pathol 2009
  8. [CrossRef] 8. Jin L, Seys AR, Zhang S, Erickson-Johnson MR, Roth CW, Evers BR, et al. Diagnostic utility of IMP3 expression in thy- roid neoplasms. A quantitative RT-PCR study. Diag Mol Pathol 2009
  9. [CrossRef] 9. Asioli S, Erickson LA, Righi A, Jin L, Volante M, Jenkins S, et al. Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Mod Pathol 2010
  10. [CrossRef] 10. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wew- er UM, Nielsen FC. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late develop- ment. Mol Cell Biol 1999
  11. Nielsen FC, Nielsen J, Christiansen J. A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking. Scand J Clin Lab Invest Suppl 2001
  12. [CrossRef] 12. M